Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
2.950
+0.060 (2.08%)
Mar 9, 2026, 2:25 PM EDT - Market open
Dogwood Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 9.86 | 8.7 | 3.72 | 4.25 | 4.85 | 9.81 | |
| Research & Development | 21.84 | 3.53 | 1.73 | 8.07 | 10.8 | 0.19 | |
| Operating Expenses | 31.7 | 12.23 | 5.45 | 12.32 | 15.64 | 10.01 | |
| Operating Income | -31.7 | -12.23 | -5.45 | -12.32 | -15.64 | -10.01 | |
| Interest Expense | -0.11 | -0.09 | - | - | - | -0.38 | |
| Interest & Investment Income | - | - | 0.15 | 0.07 | 0.01 | - | |
| Currency Exchange Gain (Loss) | -0.07 | -0.03 | - | - | - | - | |
| Other Non Operating Income (Expenses) | - | - | - | - | - | 0.04 | |
| EBT Excluding Unusual Items | -31.88 | -12.35 | -5.3 | -12.25 | -15.64 | -10.35 | |
| Legal Settlements | - | - | - | - | -0.33 | - | |
| Pretax Income | -38.02 | -12.35 | -5.3 | -12.25 | -15.96 | -10.35 | |
| Income Tax Expense | 0.19 | -0 | - | - | - | - | |
| Net Income | -38.2 | -12.35 | -5.3 | -12.25 | -15.96 | -10.35 | |
| Preferred Dividends & Other Adjustments | 1.77 | 0.51 | - | - | - | - | |
| Net Income to Common | -39.98 | -12.86 | -5.3 | -12.25 | -15.96 | -10.35 | |
| Shares Outstanding (Basic) | 2 | 1 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 84.81% | 36.84% | 69.62% | 32.91% | 69.06% | 1.96% | |
| EPS (Basic) | -24.24 | -12.52 | -7.05 | -27.66 | -47.90 | -52.50 | |
| EPS (Diluted) | -24.24 | -12.52 | -7.05 | -27.66 | -48.00 | -52.50 | |
| EBITDA | - | -12.22 | - | - | - | - | |
| D&A For EBITDA | - | 0.01 | - | - | - | - | |
| EBIT | -31.7 | -12.23 | -5.45 | -12.32 | -15.64 | -10.01 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.